Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infusional Melphalan + Bortezomib Conditioning for Multiple Myeloma
NCT02353572Phase 2Terminated
- Sponsor
- University of Colorado Denver
- Start
- Nov 2009
- Primary completion
- Sep 2011
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in multiple myeloma (MM), sponsored by University of Colorado Denver. Started Nov 2009; status: terminated.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02353572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02353572.